TRENTON (AP) - Results of a preliminary analysis of the just-completed study showed Vytorin, marketed jointly by Merck & Co. and Schering-Plough Corp., was no better than placebo at lowering the risk ...

Investors continued dumping shares of Merck & Co and Schering-Plough Corp. Tuesday, a day after their cholesterol-drug partnership took a hit from somewhat negative results of a controversial study, ...

Keith Aaronson treats some of the sickest heart patients at the University of Michigan. His patients' heart muscles are failing, and some require transplants. He used to give Zetia to those at high ...

For 12 years, there’s been a raging, multibillion-dollar controversy in the giant market for cholesterol-lowering drugs taken by 20 million or more Americans: do one set of pills, Zetia and Vytorin ...

For two decades, that has been the mantra of heart doctors and their patients: Lower LDL, or "bad" cholesterol, reduces the risk of heart attack and stroke and prolongs life. But a controversial study ...

(CBS/AP) Patients with chronic kidney disease often face other problems, including heart failure and stroke. Vytorin to the rescue? The FDA says Merck's popular cholesterol drug helps reduce ...

Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until ...

SHARP is the First and Only Prospective Clinical Study in Patients With Chronic Kidney Disease to Show That an LDL Cholesterol-Lowering Medicine Reduced Major Vascular and Atherosclerotic Events "This ...

Study analysis finds Vytorin works better than Lipitor Merck and Schering-Plough said Monday that new analysis of a previously released study of its jointly marketed Vytorin (ezetimibe/simvastatin) ...

Whitehouse Station and Kenilworth, NJ - Late last Friday afternoon it became official: FDA approval had finally arrived for Vytorin TM, the highly anticipated simvastatin/ezetimibe combination from ...

What would a new year be without a full-blown pharmaceutical controversy? Last summer there were black-box warnings for Avandia and Actos, two diabetes drugs associated with heart failure. In the fall ...